A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations

Exclusion Criteria

• •Diseases or conditions that might compromise any major body system or interfere with the pharmacokinetics of NPSP795
• •History of treatment with PTH 1-84 or 1-34 within the previous 6 months
• •History of hypocalcemia requiring frequent IV calcium infusions
• •History of hypocalcemic seizure within the past 3 months
• •Blood 25-hydroxy vitamin D level \< 25 ng/mL. If subjects have a blood 25-hydroxy vitamin D level \< 25 ng/mL at the outpatient screening visit, they will be prescribed vitamin D replacement. Once the 25-hydroxy vitamin D level is \> 25 ng/mL, the subject will be eligible to continue on to the treatment phase of the study
• •Estimated glomerular filtration rate (GFR) \< 25 mL/minute, and/or abnormal hepatic, hematologic, and/or clotting function
• •12 lead resting electrocardiogram (ECG) with clinically significant abnormalities
• •Concomitant medications with the potential to interfere with NPSP795 metabolism
• •History of thyroid or parathyroid surgery